Testing effectiveness (Phase 2)Ended earlyNCT00720629
What this trial is testing
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Who this might be right for
Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute 8